Ron Kocak
Known title: VP Controller and PAOCIK: 0002011160
Ron Kocak's purchase track record
Ron Kocak has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/8/2025 | RNXT | $10K | +62.5% | +52.5% | +34.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RNXT | ▲ Buy | Open Market | 6,500 | $5K | 4/10/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 6,000 | $5K | 4/9/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 95 | $76 | 4/8/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
RenovoRx publishes peer-reviewed case series in oncology journal
RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.
RenovoRx publishes peer-reviewed case series in oncology journal. RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.